Research programme: ROR gamma antagonists - Orca Pharmaceuticals

Drug Profile

Research programme: ROR gamma antagonists - Orca Pharmaceuticals

Alternative Names: Autoimmune disorder therapeutics - Orca Pharmaceuticasl; BBI-6000; ROR gamma antagonists; ROR gammat inhibitors; RORγt inhibitors

Latest Information Update: 28 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New York University
  • Developer New York University; Orca Pharmaceuticals; University of Oxford
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 24 Nov 2015 Brickell has the exclusive world-wide rights to a series of novel retinoic acid-related orphan nuclear receptor gamma (RORγ) inhibitors from Orca Pharmaceuticals
  • 01 Apr 2014 Preclinical trials in Autoimmune disorders in United Kingdom (PO)
  • 01 Sep 2013 Preclinical trials in Autoimmune disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top